Capital Advisors Inc. OK Boosts Position in Johnson & Johnson (NYSE:JNJ)

Capital Advisors Inc. OK increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.5% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 82,301 shares of the company’s stock after buying an additional 1,986 shares during the quarter. Capital Advisors Inc. OK’s holdings in Johnson & Johnson were worth $12,144,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Sofos Investments Inc. increased its holdings in Johnson & Johnson by 172.0% in the first quarter. Sofos Investments Inc. now owns 1,148 shares of the company’s stock valued at $33,000 after buying an additional 726 shares in the last quarter. Altshuler Shaham Ltd purchased a new position in Johnson & Johnson in the 1st quarter valued at approximately $35,000. Lake Point Wealth Management increased its stake in Johnson & Johnson by 144.4% in the 1st quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock valued at $38,000 after purchasing an additional 169 shares in the last quarter. Islay Capital Management LLC acquired a new position in Johnson & Johnson during the second quarter worth $42,000. Finally, Lion Street Advisors LLC purchased a new stake in Johnson & Johnson during the first quarter worth $45,000. Institutional investors own 67.44% of the company’s stock.

NYSE JNJ traded up $0.54 during trading hours on Tuesday, hitting $148.89. 4,375,700 shares of the company’s stock were exchanged, compared to its average volume of 8,477,668. The business’s 50 day moving average is $149.29 and its 200-day moving average is $144.17. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.99 and a current ratio of 1.25. Johnson & Johnson has a 12-month low of $109.16 and a 12-month high of $157.00. The firm has a market capitalization of $390.58 billion, a P/E ratio of 21.77, a price-to-earnings-growth ratio of 3.27 and a beta of 0.68.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Thursday, July 16th. The company reported $1.67 EPS for the quarter, beating the Zacks’ consensus estimate of $1.50 by $0.17. The company had revenue of $18.34 billion during the quarter, compared to the consensus estimate of $17.73 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The company’s quarterly revenue was down 10.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.58 EPS. As a group, equities research analysts anticipate that Johnson & Johnson will post 7.85 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a dividend of $1.01 per share. This represents a $4.04 dividend on an annualized basis and a yield of 2.71%. The ex-dividend date of this dividend was Monday, August 24th. Johnson & Johnson’s dividend payout ratio is currently 46.54%.

A number of brokerages have recently weighed in on JNJ. Credit Suisse Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Friday, September 4th. Bank of America reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, July 20th. Citigroup raised their price objective on shares of Johnson & Johnson from $165.00 to $170.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Raymond James upped their target price on Johnson & Johnson from $157.00 to $158.00 and gave the company an “outperform” rating in a research note on Friday, July 17th. Finally, Stifel Nicolaus downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $163.00.

In related news, EVP Ashley Mcevoy sold 29,000 shares of the stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the completion of the sale, the executive vice president now owns 21,682 shares of the company’s stock, valued at approximately $3,197,444.54. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Kathryn E. Wengel sold 16,115 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the sale, the executive vice president now directly owns 66,658 shares of the company’s stock, valued at approximately $10,233,336.16. The disclosure for this sale can be found here. 0.27% of the stock is owned by company insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Return on Equity (ROE)

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.